Department of Chemistry University of Florida Gainesville FL USA

Department of Histology and Embryology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Pharmacology and Therapeutics University of Florida Gainesville FL USA

Experimental Oncology and Hematology Department of Oncology and Hematology St Gallen Cantonal Hospital St Gallen Switzerland

UF Health Cancer Center University of Florida Gainesville FL USA

Zobrazit více v PubMed

Rajkumar SV. Myeloma today: disease definitions and treatment advances. Am J Hematol. 2016;91(1):90–100. PubMed PMC

Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cellsLee. Proc Natl Acad Sci U S A. 2003;100(17):9946–9951 PubMed PMC

Pluquet O, Pourtier A, Abbadie C. The unfolded protein response and cellular senescence. A review in the theme: cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. Am J Physiol Cell Physiol. 2015;308(6):C415–425. PubMed

Maiso P, Huynh D, Moschetta M, et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015;75(10):2071–2082. PubMed PMC

Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 2017;5:7. PubMed PMC

Soriano GP, Besse L, Li N, et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia. 2016;30(11):2198–2207. PubMed PMC

Thompson RM, Dytfeld D, Reyes L, et al. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. 2017;8(22):35863–35876. PubMed PMC

Riz I, Hawley TS, Marsal JW, Hawley RG. Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming. Oncotarget. 2016;7(41):66360–66385. PubMed PMC

Dytfeld D, Luczak M, Wrobel T, et al. Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget. 2016;7(35):56726–56736. PubMed PMC

Zheng Z, Fan S, Zheng J, et al. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. J Hematol Oncol. 2018;11(1):29. PubMed PMC

Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol. 2008;141(4):494–503. PubMed

Starheim KK, Holien T, Misund K, et al. Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells. Blood Cancer J. 2016;6(7):e446. PubMed PMC

Cagnetta A, Cea M, Calimeri T, et al. Intracellular NAD(+) depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013;122(7):1243–1255. PubMed PMC

Kanekura K, Ishigaki S, Merksamer PI, Papa FR, Urano F. Establishment of a system for monitoring endoplasmic reticulum redox state in mammalian cells. Lab Invest. 2013;93(11):1254–1258. PubMed PMC

Robinson RM, Reyes L, Duncan RM, et al. Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia. 2019;33(4):1011–1022. PubMed PMC

Zaal EA, Berkers CR. The Influence of metabolism on drug response in cancer. Front Oncol. 2018;8:500. PubMed PMC